

Completion of non-clinical studies and IND authorization for a 3rd generation multiple sclerosis drug candidate based on biased modulation that overcomes the limitations of cardiac side effects



| | |
|---------------------------------|--|
| IMMUNOLOGY | Preclinical |
| Product Type | Small molecule |
| Indication | multiple sclerosis |
| Target | S1P1 |
| MoA(Mechanism of Action) | Peripheral lymphocyte reduce → Inhibition of Autoimmune & Neuro-inflammation (S1P1 agonist → Functional antagonist) |
| Competitiveness | <p>CV-02 is a next-generation S1P1 modulator that minimizes cardiac side effects due to G-protein-mediated signals through signal biased control technology for S1P1 receptor</p> <p>Existing S1P1 agonists Simultaneous signaling 1st and 2nd generation drugs (unbiased drugs) Reduced efficacy Cardiac side effects • Checking Heart function • Titration period requirement</p> <p>CV-02 β-arrestin-dependent Biased signal control There are no selective β-arrestin-mediated biased ligands in clinical development. Maximize efficacy Minimize cardiac side effects • No need to check Heart function • No Titration period requirement</p> |
| Development Stage | Preclinical |
| Route of Administration | PO |